During the past decade, Märkische Kliniken GmbH conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Märkische Kliniken GmbH" are "Acute Myeloid Leukemia (AML)" (1 trials) and "Heart Failure, Congestive" (1 trials). Many other conditions were trialed in "Märkische Kliniken GmbH" in a lesser frequency.

Most popular intervention types in "Märkische Kliniken GmbH" are "Device" (1 trials) and "Drug" (1 trials). Other intervention types were less common.

The name of intervention was led by "Cardiac resynchronisation therapy" (1 trials), "Cytarabine" (1 trials), "Dasatinib" (1 trials), "Daunorubicin" (1 trials) and "Idarubicin" (1 trials). Other intervention names were less common.

The vast majority of trials in "Märkische Kliniken GmbH" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Märkische Kliniken GmbH". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Märkische Kliniken GmbH, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Märkische Kliniken GmbH, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".

Märkische Kliniken GmbH has several departments that took part in Clinical trials: "Märkische Kliniken GmbH, Klinikum Lüdenscheid; Hämatologie / Onkologie" - 2 trials, "Department of Nuclear Medicine Klinikum Luedenscheid" - 2 trials, "Maerkische Kliniken GmbH, Klinikum Luedenscheid, Innere III" - 2 trials